Precision BioSciences Expects Funding To Last Into 2029 For Two Gene-Editing Programs

The forecast rests on offering proceeds, existing cash, spending discipline and access to further share sales.

Share
Precision BioSciences Expects Funding To Last Into 2029 For Two Gene-Editing Programs

Precision BioSciences, which develops gene-editing therapies, expects its funding to last into the fourth quarter of 2029, the company said in an SEC filing Monday. That outlook would give its hepatitis B and Duchenne muscular dystrophy programs enough financial backing to reach their next key clinical development milestones, management projects.

Funding Depends On More Than The Offering

The cash outlook combines expected net proceeds from the stock-and-warrant offering with money Precision already holds. Management also assumes continued control of operating costs and access to an at-the-market facility — a way to sell additional shares into the market.

The financing was previously reported. Under an underwriting agreement signed Thursday, Precision priced 10,235,077 common shares at $7.75 each. Certain investors would receive pre-funded warrants instead of common stock, covering up to 5,893,964 shares at $7.749995 per warrant.

Pre-funded warrants let investors pay almost all the share price upfront and obtain shares through exercise. Both the common shares being offered and shares issued through warrant exercises would increase the share count; further sales through the market facility would also dilute existing holders' ownership. The fourth-quarter 2029 projection therefore rests partly on access to equity financing, alongside existing cash and spending discipline.

Hepatitis B And Duchenne Take Priority

Precision's ARCUS platform edits DNA inside the body. Its lead hepatitis B candidate, PBGENE-HBV, is being tested as a potential cure for chronic infection in an early-stage trial spanning Hong Kong, New Zealand, the United States and Moldova.

The other lead program, PBGENE-DMD, targets Duchenne muscular dystrophy. Precision has paused a separate program for a mitochondrial disease. The company's funding projection specifically covers the hepatitis B and Duchenne programs through their next key milestones.

Technology licensing also brings in money. Precision has agreements with iECURE, which is testing an ARCUS-based therapy for OTC deficiency, as well as Caribou Biosciences, TG Therapeutics and Imugene.

Precision's forecast is a statement about financing those clinical milestones, not a prediction that either treatment will succeed.

Sources

More on Precision BioSciences

All Precision BioSciences (DTIL) coverage →